Detailed SABCS analysis with Eva Segelov, Craig Underhill, Steve Vogl and Amelia McCartney.
The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 19 in our series The Oncology Journal Club, dedicated to the San Antonio Breast Cancer Symposium 2020, our last meeting focused episode of 2020.
Today’s episode features Amelia McCartney chatting with Eva Segelov, Craig Underhill and Steve Vogl from New York. It’s an entertaining and detailed discussion so we hope you find value in this expert analysis.
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.
The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.
This Week’s Papers:
- Kalinsky, K., et al. GS3-00. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). Access online here.
- Sparano, J.A., et al. GS4-10. Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer. Access online here.
- Loibl, S., et al. GS1-02 Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B. Access online here. Access online here.
- O’Shaughnessy, J. A., et al. GS1-01. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer. Access online here.
- Ganz,, P., et al. GS2-10. Targeting depressive symptoms in younger breast cancer survivors: A randomized controlled trial of mindfulness meditation and survivorship education. Access online here.
- Rugo, H. S., et al. GS3-01. Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. Access online here.
- Hurvitz, S. A., et al. GS3-06. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Access online here.
- Wang, T., et al. GS2-09. Diabetes risk reduction diet and survival following breast cancer. Access online here.
- Blondeaux,, E., et al. GS3-09. Chances of pregnancy after breast cancer, reproductive and disease outcomes: A systematic review and meta-analysis. Access online here.
- Cogan,, J. C., et al. GS3-08. Persistent controlled substance use following mastectomy with reconstruction surgery. Access online here.
- Kunkler,, I. H., et al. GS2-03. Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): Wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer: 10 year results. Access online here.
View from the Trenches: What Will You Do on Monday Morning? Chaired by Steven Vogl. Friday, 12/11/2020
This Week’s Team:
Professor Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
Dr Craig Underhill
Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
Dr Amelia McCartney is a medical oncologist who obtained her medical degree from the University of Sydney in 2004. Prior to her medical studies, she graduated with a Bachelor of Science and a Bachelor of Arts from the Australian National University. She completed her specialist training in Victoria in centres including Epworth Freemasons, the Peter MacCallum
Cancer Centre, University Hospital Geelong and Royal Melbourne Hospital.
She completed a four‐year fellowship in translational and clinical breast cancer research under the supervision and mentorship of Dr Angelo Di Leo in Prato, Italy. Dr McCartney’s particular areas of research interest are the discovery and trialling of biomarkers related to prognosis and early response to treatment, mechanisms of treatment resistance, and strategies of safely de‐escalating breast cancer therapies. . She is a serving member of several international collaborative trial committees under the auspices of the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).
Steven Vogl is a medical oncologist in private practice in the Bronx, New York. He pays attention at meetings and occasionally asks a question.
Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Eva Segelov, Craig Underhill, Amelia McCartney, Steven Vogl and Graham Knowles.